Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury - 28/08/11
Doi : 10.1016/j.jaci.2011.04.031
Sabah El-Ghaiesh, MSc a, b, Joseph P. Sanderson, PhD a, John Farrell, MPhil a, Sidonie N. Lavergne, PhD c, Wing-Kin Syn, MBChB d, e, Munir Pirmohamed, FRCP a, B. Kevin Park, PhD a, Dean J. Naisbitt, PhD a 
a MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
b Department of Pharmacology, University of Tanta, Tanta, Egypt
c University of Illinois at Urbana-Champaign, Urbana, Ill
d Centre for Liver Research, Institute of Biomedical Research, University of Birmingham, Birmingham, United Kingdom
e Department of Physiology, University of the Basque Country, Bilbao, Spain
| S.E.-G. is a PhD student funded by the Egyptian government. M.P. is an NIHR Senior Investigator and is funded by the NHS Chair of Pharmacogenetics from the United Kingdom Department of Health. This work was funded by a grant from the Wellcome Trust (078598/Z/05/Z) as part of the Centre for Drug Safety Science supported by the Medical Research Council (G0700654). |
|
| Disclosure of potential conflict of interest: D. J. Naisbitt and B. K. Park receive research support from the Medical Research Council and the Wellcome Trust. The rest of the authors have declared that they have no conflict of interest. |
© 2011
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 128 - N° 3
P. 680 - septembre 2011 Retour au numéro
Article précédent
- Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease
- Sadeep Shrestha, Howard W. Wiener, Aaron K. Olson, Jeffrey C. Edberg, Neil E. Bowles, Hitendra Patel, Michael A. Portman
- Correction
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?